Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2007
Event: Completion of the sale of the Genomic Solutions Division and Belgian subsidiary Maia Scientific (Capital Equipment Business Segment) to Digilab, Inc.
Key Financial Metrics and Transaction Terms
- Transaction Consideration: $1,000,000 in cash plus an earn-out based on 20% of revenue generated by the acquired business over a three-year period.
- Earn-out Structure: Evidenced by interest-bearing promissory notes due November 30, 2012, with prepayment options available after April 1, 2011.
- Use of Proceeds: Cash proceeds will be used to repay revolving credit loans under the Company's existing credit agreement.
- Excluded Assets: The COPAS flow cytometry product line (held by Union Biometrica US and German subsidiaries) was not included in the sale and remains in discontinued operations.
Material Changes and Strategic Shifts
The Company exited its Capital Equipment Business Segment through the disposition of the Genomic Solutions Division and Maia Scientific. This transaction represents a strategic shift to divest non-core assets. The Company has entered into non-competition and non-solicitation agreements with the Buyer for a period of three years, prohibiting engagement in the Capital Equipment Business or solicitation of Buyer's employees.
Outlook, Risks, and Contingencies
- Future Transactions: Harvard Bioscience intends to pursue a separate sale of the COPAS flow cytometry product line.
- Financial Impact: Pro forma consolidated financial information regarding the transaction is filed as Exhibit 99.1.
- Contingencies: Future cash flows are contingent on the performance of the sold business under the earn-out provision.
Investor Verification Checklist
- Verify the specific terms of the earn-out calculation and the performance of the sold business under Digilab's management.
- Review the Pro Forma Financial Information (Exhibit 99.1) to understand the impact on the Company's consolidated balance sheet and income statement.
- Confirm the status and timeline for the intended separate sale of the COPAS flow cytometry product line.
- Assess the reduction in debt levels resulting from the application of the $1,000,000 cash proceeds to revolving credit loans.